Neuromuscular Disorders
News from the FDA/CDC
FDA approves Emflaza for Duchenne muscular dystrophy
Emflaza (deflazacort) becomes the first corticosteroid to be approved by the Food and Drug Administration for Duchenne muscular dystrophy.
Patient Information
Tips for Living With Tardive Dyskinesia
Tardive dyskinesia is a movement disorder characterized by repetitive, involuntary muscle tics. These movements may occur occasionally or...
Patient Information
Tips for Living With Suspected CTE
Chronic traumatic encephalopathy (CTE) is a progressive degenerative brain disease found in athletes, military personnel, and people with...
From the Journals
New histopathologic marker may aid dermatomyositis diagnosis
The detection of sarcoplasmic myxovirus resistance A expression in immunohistochemical analysis of muscle biopsy in patients suspected of having...
From the Journals
Meningococcal conjugate vaccination may be associated with increased risk of Bell’s palsy
Meningococcal conjugate vaccine plus another vaccine may be associated with increased risk of Bell’s palsy.
Conference Coverage
What’s New in Rare Neuromuscular Disorders?
LAS VEGAS—At the American Academy of Neurology’s Fall 2016 Conference, Robert M. Pascuzzi, MD, presented several case videos to illustrate recent...
Article
Is physician-assisted suicide compatible with the Hippocratic Oath?
Do we stand by our Hippocratic Oath when providing physician-assisted suicide?Physician-assisted suicide (PAS) is a form of euthanasia in which a...
Conference Coverage
What Are New and Potential Therapies for Neuromuscular Disorders?
HILTON HEAD, SC—Biologics, stem cells, and gene therapy may hold promise as treatments for neuromuscular disorders. Ongoing clinical trials are...
From the Journals
Further evidence links Zika, Guillain-Barré syndrome
Zika virus found in Colombian patients with Guillain-Barré syndrome supports the theory that Zika virus infection and Guillain-Barré syndrome are...
From the Journals
Incontinence trial finds small advantage for Botox over sacral neuromodulation
OnabotulinumtoxinA decreased daily episodes of urinary incontinence by a small amount, compared with sacral neuromodulation, but did not appear to...